A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

Phase 1 Completed 17 enrolled Kowa Research Institute, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with and without Cirrhosis.

Timeline

Start: 2024-10-01
Primary completion: 2025-03-12
Completion: 2025-04-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	K-877	Unknown	—	—

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

Summary

Timeline

Drugs

Indications